A genomic test for the human papillomavirus has shown promise in early-stage trials, raising hopes that it could bolster cervical cancer screening among women living in sub-Saharan Africa, the region ...

The addition of human papillomavirus (HPV) DNA testing to either conventional or liquid-based cytology has previously been shown to increase detection rates of high-grade cervical intraepithelial ...

Scientists at Mass General Brigham have created HPV-DeepSeek, a blood test that can detect HPV-linked head and neck cancers nearly a decade before diagnosis. By finding viral DNA in the bloodstream, ...

Human papillomavirus (HPV) is a DNA virus known to cause infections in mucous membranes and skin, typically resulting in warty lesions. While often benign, these lesions do have the potential to ...

Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing advanced or recurrent gynecological cancers.

A new blood test can identify cancers of the head and neck caused by the human papillomavirus (HPV) up to 10 years before symptoms appear. This is the discovery of Mass General Brigham researchers who ...

Most of the currently available circulating tumor DNA (ctDNA) technologies provide a high level of diagnostic accuracy for detecting human papillomavirus (HPV)-associated oropharyngeal squamous cell ...

Human papillomavirus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year. Unlike cervical ...

Promising new inroads into critical DNA testing has been forecast by experts who have applied machine learning to DNA profiling. From medical diagnostics to forensic tests and national security, PCR ...